ClearSale
Who Is the Company Behind ClearSale?
- Seller: ClearSale
- Year Founded: 2001
- HQ Location: Denver, US
-
LinkedIn® Page: www.linkedin.com
13 employees on LinkedIn®
Last updated: April 9, 2026
Total Products under this Category: 1,412
Last updated: November 01, 2026
Why You Can Trust G2's Software Rankings:
G2's software rankings are built on verified user reviews, rigorous moderation, and a consistent research methodology maintained by a team of analysts and data experts. Each product is measured using the same transparent criteria, with no paid placement or vendor influence. While reviews reflect real user experiences, which can be subjective, they offer valuable insight into how software performs in the hands of professionals. Together, these inputs power the G2 Score, a standardized way to compare tools within every category.

Highlighted products: Gemini platform, SAS Viya, Google Cloud Recommendations AI, IBM watsonx.ai, Azure OpenAI Service, Amazon Personalize, Alteryx, and Google Cloud TPU.
Underlying data: [Grid® JSON](https://www.g2.com/categories/machine-learning/grids.json?focus%5B%5D=gemini-platform&focus%5B%5D=sas-sas-viya&focus%5B%5D=google-cloud-recommendations-ai&focus%5B%5D=ibm-watsonx-ai&focus%5B%5D=azure-openai-service&focus%5B%5D=amazon-personalize&focus%5B%5D=alteryx&focus%5B%5D=google-cloud-tpu)
Clearwell AI is an asset lifecycle intelligence platform designed to transform traditional, event-driven asset management into a continuous, data-driven process. By integrating data from various sources—including field inspections, robotic surveys, drone imagery, and sensor feeds—Clearwell AI creates a comprehensive, evolving record for each asset. This approach enables asset owners and inspection contractors to make informed decisions, optimize maintenance strategies, and extend asset life while managing budgets effectively. Key Features and Functionality: - Comprehensive Data Integration: Aggregates information from diverse inputs such as field technicians, remote-operated vehicles (ROVs), drones, SCADA systems, and historical records into a unified asset record. - AI-Powered Analysis: Utilizes artificial intelligence to categorize findings across safety, security, structural integrity, and coating conditions, assigning priorities and providing evidence-backed recommendations. - Continuous Monitoring: Supports ongoing data collection and analysis, moving beyond episodic inspections to a continuous asset management model. - Asset Owner Portal: Offers asset owners a dedicated portal with full asset history, AI-driven risk assessments, and comprehensive evidence packages, ensuring transparency and informed decision-making. - Security and Data Ownership: Built with enterprise-grade security features, including single sign-on (SSO), role-based access controls (RBAC), encryption, and compliance with standards like CCPA and GDPR, ensuring that data remains secure and under the owner's control. Primary Value and Problem Solved: Clearwell AI addresses the limitations of traditional, event-driven asset management by providing a continuous, integrated approach to asset intelligence. This system enables asset owners and inspection contractors to: - Enhance Decision-Making: Access real-time, comprehensive data to make informed maintenance and repair decisions, reducing the risk of unexpected failures. - Optimize Maintenance Strategies: Prioritize repairs and maintenance based on AI-driven analysis, ensuring resources are allocated effectively to extend asset life without inflating budgets. - Improve Compliance and Reporting: Maintain a living, detailed record of each asset, facilitating compliance with industry standards and providing clear evidence for regulatory reporting. - Increase Operational Efficiency: Streamline inspection workflows, reduce the time from data collection to actionable insights, and minimize downtime associated with maintenance activities. By transforming raw inspection data into a dynamic, intelligent asset record, Clearwell AI empowers organizations to proactively manage their assets, mitigate risks, and achieve greater operational efficiency.
Connect G2 to Claude or ChatGPT for answers grounded in G2's trusted reviews, comparisons, and pricing from real user insights.
The fastest way from research to production - cnvrg.io is an end to end data science platform that provides everything your team needs. Accelerate time from research to production with an all-in-one ML platform with advanced model management and MLOps, optimized for production.
Average Rating: 5.0/5.0
Total Reviews: 1
Rating: 4.5/5.0 stars
— Krish s.
Rating: 5.0/5.0 stars
— Verified User in Entertainment
AI platform that forecasts schedule risk for construction projects, ranks critical activities, and quantifies mitigation impact.
Cofactor Genomics is a biotechnology company specializing in RNA-based predictive diagnostics to enhance precision medicine, particularly in oncology. By analyzing RNA expression profiles, Cofactor develops diagnostic tools that predict patient responses to immunotherapies, aiming to improve treatment outcomes and reduce unnecessary interventions. Their flagship product, OncoPrism®, utilizes machine learning to assess tumor RNA, providing clinicians with actionable insights into immune engagement and therapy responsiveness. This approach addresses the limitations of traditional single-analyte biomarkers by offering a multidimensional perspective on tumor biology. Key Features and Functionality: - RNA-Based Immune Profiling: Cofactor's ImmunoPrism™ platform analyzes RNA from formalin-fixed paraffin-embedded (FFPE) tumor samples to quantify immune cell presence and activity, offering a comprehensive view of the tumor microenvironment. - Machine Learning Integration: The company employs advanced machine learning algorithms to interpret complex RNA data, identifying patterns that predict patient responses to immunotherapies. - Multidimensional Biomarkers: Moving beyond traditional single-analyte biomarkers, Cofactor develops multidimensional RNA biomarkers that provide a more accurate and nuanced understanding of tumor behavior and immune interactions. - Clinical Validation: Products like OncoPrism® have undergone rigorous clinical validation, demonstrating their efficacy in predicting immunotherapy responses across various solid tumor types. Primary Value and User Solutions: Cofactor Genomics addresses the critical challenge of matching cancer patients with the most effective immunotherapies. By providing predictive diagnostics based on RNA analysis, they enable clinicians to make informed treatment decisions, potentially increasing the success rates of immunotherapies and minimizing exposure to ineffective treatments. This personalized approach not only enhances patient outcomes but also contributes to more efficient and cost-effective healthcare delivery.
